A carregar...
Lipoprotein(a) and PCSK9 inhibition: clinical evidence
Compelling evidence has emerged from epidemiological and Mendelian randomization analyses relative to the causality of lipoprotein(a) [Lp(a)] in atherosclerotic cardiovascular diseases (ASCVD), being elevated Lp(a) a strong risk factor regardless of the reduction of LDL-C achieved by statins. So far...
Na minha lista:
| Publicado no: | Eur Heart J Suppl |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7673619/ https://ncbi.nlm.nih.gov/pubmed/33239979 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/suaa135 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|